Matthew J. Simon

Matthew J. Simon

Auto-generated profile, based on publicly available information

Matthew J. Simon

Denali Therapeutics Inc., South San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
DZDouglas M. Zeppenfeld
Douglas M. Zeppenfeld
MSMatthew Simon
Matthew Simon
JHJ. Douglas Haswell
J. Douglas Haswell
DDDaryl D’abreo
Daryl D’abreo
CMCharles Murchison
Charles Murchison
JIJeffrey J. Iliff
Jeffrey J. Iliff
Advancing age is the strongest risk factor for the development of neurodegenerative disorders such as Alzheimer disease (AD).1 A common feature of these diseases is the age-associated accumulation of protein aggregates, including senile plaques comprised of amyloid-β (Aβ) 1-42 in AD, α-synuclein within Lewy bodies in Parkinson disease and Lewy body dementia, and hyperphosphorylated tau within neurofibrillary tangles in AD and chronic traumatic encephalopathy,2 yet the upstream changes that render the aging brain vulnerable to the misaggregation of proteins remain unknown.

1 March 2016 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
MSMatthew J. Simon
Matthew J. Simon
JIJeffrey J. Iliff
Jeffrey J. Iliff

14 August 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
SBScarlett J. Barker
Scarlett J. Barker
MTMai B. Thayer
Mai B. Thayer
CKChaeyoung Kim
Chaeyoung Kim
DTDavid Tatarakis
David Tatarakis
MSMatthew J. Simon
Matthew J. Simon
SDSarah L. DeVos
Sarah L. DeVos
Antisense oligonucleotides (ASOs) are promising therapeutics for treating various neurological disorders. However, ASOs are unable to readily cross the mammalian blood-brain barrier (BBB) and therefore need to be delivered intrathecally to the central nervous system (CNS). Here, we engineered a human transferrin receptor 1 (TfR1) binding molecule, the oligonucleotide transport vehicle (OTV), to transport a tool ASO across the BBB in human TfR knockin (TfR mu/hu KI) mice and nonhuman primates. Intravenous injection and systemic delivery of OTV to TfR mu/hu KI mice resulted in sustained knockdown of the ASO target RNA, Malat1 , across multiple mouse CNS regions and cell types, including endothelial cells, neurons, astrocytes, microglia, and oligodendrocytes. In addition, systemic delivery of OTV enabled Malat1 RNA knockdown in mouse quadriceps and cardiac muscles, which are difficult to target with oligonucleotides alone. Systemically delivered OTV enabled a more uniform ASO biodistribution profile in the CNS of TfR mu/hu KI mice and greater knockdown of Malat1 RNA compared with a bivalent, high-affinity TfR antibody. In cynomolgus macaques, an OTV directed against MALAT1 displayed robust ASO delivery to the primate CNS and enabled more uniform biodistribution and RNA target knockdown compared with intrathecal dosing of the same unconjugated ASO. Our data support systemically delivered OTV as a potential platform for delivering therapeutic ASOs across the BBB.

26 May 2017 in Alzheimer's & Dementia: Translational Research & Clinical Interventions
Verified
Journal Article
Open access
KBKevin G. Burfeind
Kevin G. Burfeind
CMCharles F. Murchison
Charles F. Murchison
SWShawn K. Westaway
Shawn K. Westaway
MSMatthew J. Simon
Matthew J. Simon
DEDeniz Erten‐Lyons
Deniz Erten‐Lyons
JIJeffrey J. Iliff
Jeffrey J. Iliff
Introduction: The glymphatic system is a brain‐wide perivascular network that facilitates clearance of proteins, including amyloid β, from the brain interstitium through the perivascular exchange of cerebrospinal fluid and interstitial fluid. The astrocytic water channel aquaporin‐4 (AQP4) is required for glymphatic system function, and impairment of glymphatic function in the aging brain is associated with altered AQP4 expression and localization. In human cortical tissue, alterations in AQP4 expression and localization are associated with Alzheimer's disease (AD) status and pathology. Although this suggests a potential role for AQP4 in the development or progression of AD, the relationship between of naturally occurring variants in the human AQP4 gene and cognitive function has not yet been evaluated. Methods: Using data from several longitudinal aging cohorts, we investigated the association between five AQP4 single‐nucleotide polymorphisms (SNPs) and the rate of cognitive decline in participants with a diagnosis of AD. Results: None of the five SNPs were associated with different rates of AD diagnosis, age of dementia onset in trial subjects. No association between AQP4 SNPs with histological measures of AD pathology, including Braak stage or neuritic plaque density was observed. However, AQP4 SNPs were associated with altered rates of cognitive decline after AD diagnosis, with two SNPS (rs9951307 and rs3875089) associated with slower cognitive decline and two (rs3763040 and rs3763043) associated with more rapid cognitive decline after AD diagnosis. Discussion: These results provide the first evidence that variations in the AQP4 gene, whose gene product AQP4 is vital for glymphatic pathway function, may modulate the progression of cognitive decline in AD.

16 May 2017 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
MSMatthew J. Simon
Matthew J. Simon
CMCharles Murchison
Charles Murchison
JIJeffrey J. Iliff
Jeffrey J. Iliff

5 June 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
MRMarvin Reich
Marvin Reich
MSMatthew J. Simon
Matthew J. Simon
BPBeate Polke
Beate Polke
IPIñaki Paris
Iñaki Paris
GWGeorg Werner
Georg Werner
CHChristian Haass
Christian Haass
Progranulin (PGRN) haploinsufficiency is a major risk factor for frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43) pathology (FTLD- GRN ). Multiple therapeutic strategies are in clinical development to restore PGRN in the CNS, including gene therapy. However, a limitation of current gene therapy approaches aimed to alleviate FTLD-associated pathologies may be their inefficient brain exposure and biodistribution. We therefore developed an adeno-associated virus (AAV) targeting the liver (L) to achieve sustained peripheral expression of a transferrin receptor (TfR) binding, brain-penetrant (b) PGRN variant [AAV(L):bPGRN] in two mouse models of FTLD- GRN , namely, Grn knockout and GrnxTmem106b double knockout mice. This therapeutic strategy avoids potential safety and biodistribution issues of CNS-administered AAVs and maintains sustained concentrations of PGRN in the brain after a single dose. AAV(L):bPGRN treatment reduced several FTLD- GRN –associated pathologies including severe motor function deficits, aberrant TDP-43 phosphorylation, dysfunctional protein degradation, lipid metabolism, gliosis, and neurodegeneration in the brain. The potential translatability of our findings was tested in an in vitro model using cocultured human induced pluripotent stem cell (hiPSC)–derived microglia lacking PGRN and TMEM106B and wild-type hiPSC-derived neurons. As in mice, aberrant TDP-43, lysosomal dysfunction, and neuronal loss were ameliorated after treatment with exogenous TfR-binding protein transport vehicle fused to PGRN (PTV:PGRN). Together, our studies suggest that peripherally administered brain-penetrant PGRN replacement strategies ameliorate FTLD- GRN relevant phenotypes including TDP-43 pathology, neurodegeneration, and behavioral deficits. Our data provide preclinical proof of concept for the use of this AAV platform for treatment of FTLD- GRN and potentially other CNS disorders.